Sirolimus/steroids Maintenance Therapy after Early Cyclosporine Withdrawal: 12-month Efficacy and Safety Results of Multicenter Single Arm Pilot Study in Primary Renal Allograft Recipients in Korea
نویسندگان
چکیده
261 Correspondence to: Yu Seun Kim, Department of Transplantation Surgery, Severance Hospital, Yonsei University Health System 134, Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea. Tel: 02-2228-2115, Fax: 02-313-8289, E-mail: [email protected] Co-correspondence to: Duck-Jong Han, Department of Surgery, Asan Medical Center 86, Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, Korea. Tel: 02-3010-3487, Fax: 02-474-9027, E-mail: [email protected] Received May 23, 2010, Accepted July 2, 2010 This multi-center clinical study (protocol No. 102362) led by Dr. Duck-Jong Han was supported by Wyeth Korea, Inc., Seoul, Korea. Sirolimus/steroids Maintenance Therapy after Early Cyclosporine Withdrawal: 12-month Efficacy and Safety Results of Multicenter Single Arm Pilot Study in Primary Renal Allograft Recipients in Korea
منابع مشابه
Early cyclosporine a withdrawal in kidney transplant recipients under a sirolimus-based immunosuppressive regimen: pathological study of graft biopsies at 1-year posttransplant.
THE ROLE of anticalcineurin agents, cyclosporine A (CyA) and tacrolimus (TRC), in the development of chronic allograft nephropathy (CAN) and subsequently in long-term graft survival seems to be of major importance owing to their nephrotoxic effect. Unfortunately, no successful alternatives are available to date. Sirolimus has shown a similar efficacy to CyA when used alone with respect to graft...
متن کاملEarly cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
BACKGROUND Nephrotoxicity of calcineurin inhibitors (CNIs) is partially responsible for the development of chronic allograft nephropathy (CAN). Sirolimus has demonstrated its potential to substitute for CNIs because it lacks significant nephrotoxicity and shows a short-term immunosuppressive capacity comparable with that of cyclosporine. This results in the maintenance of better renal function ...
متن کاملSirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
BACKGROUND Sirolimus reduces acute rejection in renal transplant recipients and prevents vasculopathy in nonhuman primates and in-stent restenosis in humans. Its effects on rejection and transplant vasculopathy in human heart transplant recipients are unknown. METHODS AND RESULTS In a randomized, open-label study, sirolimus was compared with azathioprine in combination with cyclosporine and s...
متن کاملSteroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis.
Data from seven randomized, prospective trials were pooled to determine the effect of steroid-free immunosuppression on allograft survival, patient survival, and the incidence of acute allograft rejection in renal transplant recipients receiving cyclosporine-based maintenance immunosuppression. Six of the seven trials incorporated into this analysis examined the effects of either complete avoid...
متن کاملA Randomized 2×2 Factorial Trial, Part 1: Single-Dose Rabbit Antithymocyte Globulin Induction May Improve Renal Transplantation Outcomes
BACKGROUND We conducted a randomized and unblinded 2 × 2 sequential-factorial trial, composed of an induction arm (part 1) comparing single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a maintenance arm (part 2) comparing tacrolimus minimization versus withdrawal. We report the long-term safety and efficacy of SD-rATG induction in the context of early steroid withdraw...
متن کامل